Sign In
Buy RYTM
$84.71
+0.360 (+0.427%)
At Close: Jun 03, 2026
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
02:58am, Wednesday, 03'rd Jun 2026
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE's recent FDA and EU a
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
08:00am, Friday, 29'th May 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
08:00am, Tuesday, 26'th May 2026
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
11:00pm, Wednesday, 13'th May 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
08:00am, Tuesday, 12'th May 2026
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
My Top 3 Stocks to Buy in May
04:44am, Thursday, 07'th May 2026
Forget "sell in May and go away." These stocks are good picks to buy and hold.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
02:04pm, Wednesday, 06'th May 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
08:00am, Wednesday, 06'th May 2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
05:31pm, Tuesday, 05'th May 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
09:26am, Tuesday, 05'th May 2026
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
07:00am, Tuesday, 05'th May 2026
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- --
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
08:00am, Monday, 04'th May 2026
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pedi
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
11:02am, Wednesday, 29'th Apr 2026
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
